In 2017, we received funding from CIHR’s Partnership for Health Systems Improvement initiative for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) collaboration. This collaboration will develop a framework for the generation and use of Real World Evidence (RWE) for cancer drug funding decisions in Canada.
The CanREValue collaboration brings together key stakeholders including ARCC, CADTH/ pCODR, CAPCA, Health Canada, INESSS, Ministries/departments of Health, pCPA, PMPRB, and provincial cancer agencies from across Canada. By providing a platform for stakeholders to discuss their needs and existing evidence gaps, the CanREValue collaboration will enable knowledge exchange, and address policy relevant research questions.
Contact us: CanREValue@cc-arcc.ca
https://cc-arcc.ca/wp-content/uploads/2018/07/CanRevalue-logo.jpg
237
872
Rebecca Mercer
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png
Rebecca Mercer2022-03-11 11:01:552022-03-11 11:02:57New Publication: Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
https://cc-arcc.ca/wp-content/uploads/2018/07/CanRevalue-logo.jpg
237
872
Rebecca Mercer
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png
Rebecca Mercer2022-03-08 12:04:392022-03-15 12:11:47New Publication: Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer
https://cc-arcc.ca/wp-content/uploads/2018/07/CanRevalue-logo.jpg
237
872
Rebecca Mercer
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png
Rebecca Mercer2021-10-26 10:36:302021-10-26 10:37:01New Publication: Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group
https://cc-arcc.ca/wp-content/uploads/2018/07/CanRevalue-logo.jpg
237
872
Rebecca Mercer
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png
Rebecca Mercer2021-06-22 09:50:262021-06-22 09:50:26New Publication: Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces
Patient perspectives of Value Frameworks used to Guide Oncology Treatment DecisionsMay 1, 2021 - 12:27 pmUnderstanding British Columbia cancer patients’ experiences with virtual health before and during the COVID-19 pandemicMay 1, 2021 - 11:53 amBenchmarking End of Life Quality Indicators by Tumor Type & Describing models of palliative care across CanadaApril 1, 2021 - 8:56 amEvaluation of the systemic cancer therapy volume-outcome association: a population-based study to inform the optimal provincial organization and delivery of systemic cancer therapyFebruary 1, 2021 - 12:20 pm
